公开(公告)号：EP1502602A3

公开(公告)日：2006-05-17

申请号：EP04076709.7

申请日：1999-10-05

申请人： Pharmexa A/S

发明人： Steinaa, Lucilla ,  Mouritsen, Soren ,  Nielsen, Klaus Gregorius ,  Haaning, Jesper ,  Leach, Dana ,  Dalum, Iben ,  Gautam, Anand ,  Rasmussen, Peter Birk ,  Karlsson, Gunilla

IPC分类号： A61K38/17 ,  A61K38/18 ,  C07K14/50 ,  C07K14/705 ,  C07K14/71 ,  C12N15/63 ,  C12N5/16 ,  C12N15/12

CPC分类号： C07K16/3069 ,  A61K39/00 ,  A61K39/0011 ,  A61K2039/6081 ,  C07K2317/34 ,  Y02A50/412

摘要： A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells aer disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.

公开(公告)号：EP1502602A2

公开(公告)日：2005-02-02

申请号：EP04076709.7

申请日：1999-10-05

申请人： Pharmexa A/S

发明人： Steinaa, Lucilla ,  Mouritsen, Soren ,  Nielsen, Klaus Gregorius ,  Haaning, Jesper ,  Leach, Dana ,  Dalum, Iben ,  Gautam, Anand ,  Rasmussen, Peter Birk ,  Karlsson, Gunilla

IPC分类号： A61K39/39 ,  A61K38/17 ,  A61K38/18 ,  C07K14/50 ,  C07K14/705 ,  C07K14/71 ,  C12N15/63 ,  C12N5/16 ,  C12N15/12

CPC分类号： C07K16/3069 ,  A61K39/00 ,  A61K39/0011 ,  A61K2039/6081 ,  C07K2317/34 ,  Y02A50/412

摘要： A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells aer disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.

摘要翻译： 公开了诱导针对细胞抗原的细胞介导的免疫的方法。 更具体地，本发明提供了针对弱抗原，特别是自身蛋白诱导细胞毒性T淋巴细胞免疫的方法。 该方法要求诱导抗原呈递细胞呈现弱抗原的至少一个CTL表位，同时呈现至少一种外源性T辅助淋巴细胞表位。 在优选的实施方案中，抗原是癌特异性抗原，例如， PSM，Her2或FGF8b。 该方法可以通过使用传统的多肽疫苗接种，也可以通过使用活减毒疫苗或核酸接种来进行。 本发明还提供PSM，Her2和FGF8b的免疫原性类似物以及编码这些类似物的核酸分子。 还公开了载体和转化细胞。 本发明还提供了用于鉴定弱或非免疫原性抗原的免疫原性类似物的方法。